TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00844012
Drug: Cyclic OC (clormadinone acetate plus ethinil-estradiol)
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
Study: NCT01271725
Drug: Vinorelbine 25 mg/m2 weekly
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
Study: NCT01271725
Drug: Afatinib 40mg once daily (OD)
Normalized name: lisinopril
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
Study: NCT01271725
Drug: Paclitaxel 80 mg/m2 weekly
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
Study: NCT01702025
Drug: Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: National Drug Code (NDC) 0143-1020-01
Study: NCT01702025
Drug: Methazolamide
Normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDC 0781-1072-01
Study: NCT01702025
Drug: Aminophylline+Methazolamide
Normalized name: Methazolamide
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDC 0143-1020-01 and NDC 0781-1072-01
Study: NCT03053401
Drug: local anaesthetic injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
Study: NCT00533169
Drug: Retinoic Acid
Normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
Study: NCT03802240
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV Q3W
Study: NCT03802240
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg/m2 IV Q3W
Study: NCT03802240
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 IV Q3W
Study: NCT00704938
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m\^2 (Days -5, -4, -3, -2, and -1)
Study: NCT02282891
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction of general anesthesia using propofol 2mg/kg
Study: NCT02282891
Drug: Propofol-Ketamine
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
Study: NCT04572698
Drug: Eylea
Normalized name: Eylea
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
Study: NCT03321890
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
Study: NCT03321890
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 20mg / day,after breakfast
Study: NCT03321890
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 50mg / day,after dinner
Study: NCT00380406
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01137292
Drug: voriconazole (VFEND®)
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
Study: NCT02524444
Drug: Mefloquine
Normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tabs Mefloquine 250mg
Study: NCT02524444
Drug: Sulphadoxine-Pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphadoxine 500mg , Pyrimethamine 25mg
Study: NCT03386929
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
Study: NCT03386929
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
Study: NCT03386929
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
Study: NCT03425162
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient-controlled analgesia (PCA) morphine
Study: NCT00038103
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
Study: NCT06015594
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients treated with metformin
Study: NCT00662636
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT00662636
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT01517828
Drug: Sedation by ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
Study: NCT01517828
Drug: Sedation with Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done.
Study: NCT01262859
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
Study: NCT01900405
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00117364
Drug: SACCHACHITIN patch
DrugBank: Chitin (DB15142)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03264456
Drug: [18F] fluciclovine
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: \[18F\] fluciclovine
Study: NCT02987335
Drug: Pancreatic Clamp
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
Study: NCT04419662
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect.
Study: NCT03234816
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Bupivacaine intra-thecal for spinal anesthesia
Study: NCT03254394
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study.
Study: NCT02473562
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet 1 mg BID
Study: NCT00350831
Drug: XL820
Normalized name: XL820
DrugBank: XL820 (DB05146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00089258
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00890786
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5.
Study: NCT00890786
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days).
Study: NCT00890786
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days).
Study: NCT01670110
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injectible, 60mg per month
Study: NCT01172626
Drug: valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration,15-30mg/kg,daily
Study: NCT03418324
Drug: TRC105
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
DrugBank: Carotuximab (DB06322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
Study: NCT03418324
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
Study: NCT03418324
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
Study: NCT00195078
Drug: ZD1839 (IRESSA)
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00195078
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03385148
Drug: 68Ga-Sgc8
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
Study: NCT02300259
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02300259
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02300259
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00908336
Drug: Docetaxel and Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
Study: NCT00908336
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day po daily
Study: NCT01390402
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
Study: NCT01390402
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/ m2 by vein for 2 doses on Days -11 to -10.
Study: NCT04042324
Drug: Triferic
Normalized name: Triferic
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
Study: NCT02804126
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
Study: NCT02804126
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study: NCT02804126
Drug: Metamizol
Normalized name: Metamizol
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
Study: NCT02804126
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Study: NCT00889512
Drug: Luveris increasing dose
Normalized name: Luveris
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
Study: NCT01390402
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
Study: NCT01390402
Drug: Anti-Thymocyte Globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg by vein for 3 doses on Days -3 to -1.
Study: NCT01390402
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
Study: NCT01390402
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
Study: NCT04628429
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CGRP-receptor monoclonal anti-body
Study: NCT04628429
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anti-CGRP-ligand monoclonal anti-body
Study: NCT04628429
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CGRP-ligand monoclonal anti-body
Study: NCT00681889
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 Patients will receive treatment (Ranibizumab)
Study: NCT00640848
Drug: almorexant
Normalized name: Almorexant
DrugBank: Almorexant (DB06673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 400 mg in two treatment sequences
Study: NCT00640848
Drug: almorexant
Normalized name: Almorexant
DrugBank: Almorexant (DB06673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 200 mg in two treatment sequences
Study: NCT00640848
Drug: almorexant
Normalized name: Almorexant
DrugBank: Almorexant (DB06673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 100 mg in two treatment sequences
Study: NCT00640848
Drug: almorexant
Normalized name: Almorexant
DrugBank: Almorexant (DB06673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 50 mg mg in two treatment sequences
Study: NCT00640848
Drug: almorexant
Normalized name: Almorexant
DrugBank: Almorexant (DB06673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 1000 mg in two treatment sequences
Study: NCT02772744
Drug: Daclatasvir 60 MG Oral Tablet [Daklinza]
Normalized name: Daclatasvir 60 MG Oral Tablet [DAKLINZA]
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
Study: NCT02772744
Drug: Sofosbuvir 400 MG Oral Tablet [Sovaldi]
Normalized name: Sofosbuvir 400 MG Oral Tablet [SOVALDI]
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
Study: NCT02772744
Drug: Ribavirin Oral Product
Normalized name: ribavirin Oral Product
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
Study: NCT00655629
Drug: Vardenafil ODT (STAXYN, BAY38-9456)
Normalized name: Vardenafil Orally Disintegrating Tablets
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
Study: NCT00654082
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
Study: NCT03529890
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1
Study: NCT02511886
Drug: Arbaclofen Placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen Placarbil
Study: NCT01362608
Drug: Canakinumab, ACZ885
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab and placebo matching to triamcinolone acetonide
Study: NCT01362608
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 40 mg and placebo matching to canakinumab
Study: NCT03403439
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference and Test Treatment
Study: NCT03403439
Drug: itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test treatment